Choose a language and wait for the translated text.
Shots:
The US FDA has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) with fluoropyrimidine & oxaliplatin for the adj. treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer
Approval was based on the P-III (ATOMIC) trial in above-mentioned pts (n=712), which were randomized to either mFOLFOX6 plus Tecentriq for 12 cycles followed by Tecentriq monotx. for 13 cycles, or mFOLFOX6 alone for 12 cycles
Trial showed a 50% reduction in the risk of disease recurrence or death, plus a 36mos. DFS rate of 86% vs 76%; data were published in The NEJM
Ref: Businesswire | Image: Genentech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post The US FDA Approves Genentech’s Tecentriq Combination for Stage III dMMR Colon Cancer appeared first on PharmaShots.
